Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BAY3389934
BAY 3389934 · 1 trial · 1 indication
Investigate the safety and tolerability of BAY 3389934 15 mg/h and a second, higher dose (will be determined based on the result of 15 mg/h dose step), 4-hours infusion, respectively.
| Arm | Type | Description |
|---|---|---|
| Dose Step 1 BAY 3389934 | EXPERIMENTAL | 15 mg/h/ intravenous Single Dose for 4 h fasting |
| Dose Step 2 BAY 3389934 | EXPERIMENTAL | Max. dose 35 mg / h / intravenous - actual dose will be determined after Dose Step 1 Single Dose for 4 h fasting |
| Dose Step 1 and Dose Step 2 Placebo | PLACEBO_COMPARATOR | Placebo / intravenous Single Dose for 4 h Fasting |
| Name | Type | Description |
|---|---|---|
| BAY 3389934 | DRUG | Solution for intravenous infusion |
| Matching Placebo / Diluent | DRUG | Solution for intravenous infusion |
Inclusion Criteria: * Participant must be 18 to 55 years of age inclusive. * Participants who are overtly healthy Japanese as determined by medical evaluation. * Body mass index (BMI) within the range 18 - 29.9 kg/m² (inclusive). * Male participants must agree to use specified contraception ...
BAY 3389934 is an investigational small molecule being developed for sepsis, sepsis associated disseminated intravascular coagulation (DIC), and drug-drug interaction studies. It is being studied in patients with sepsis induced coagulopathy and in healthy volunteers to assess its safety, dosing, and effects on blood clotting.
BAY 3389934 is being developed by Bayer AG, a German pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker symbol BAYRY. The drug is currently in Phase 1 clinical development for hematology indications.
BAY 3389934 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Multiple Phase 1 trials are ongoing or completed to evaluate its safety, tolerability, and pharmacological effects in healthy volunteers and patients with sepsis induced coagulopathy.
BAY 3389934 is being studied in several Phase 1 trials. NCT06854640 is recruiting patients with sepsis induced coagulopathy in Belgium, France, Germany, and the Netherlands. NCT07176728 was completed in healthy Japanese volunteers. NCT07652723 is recruiting healthy participants in the United States to study drug-drug interactions with aspirin.
Yes, BAY 3389934 and BAY3389934 refer to the same investigational drug. The compound is being developed by Bayer AG under these interchangeable names. Clinical trial NCT07652723 uses the name BAY3389934, while other trials use BAY 3389934.